Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipoprotein-associated phospholipase A2.

Joseph P McConnell1, Daniel M Hoefner

  • 1Department of Laboratory Medicine and Pathology, The Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA. mcconnell.joseph@mayo.edu

Clinics in Laboratory Medicine
|August 30, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Comparing neutralizing antibody activity over time between naïve and convalesced COVID-19 vaccinated individuals.

Scientific reports·2025
Same author

Comparing neutralizing antibody activity over time between naïve and convalesced COVID-19 vaccinated individuals.

Scientific reports·2025
Same author

Chylous Ascites: Reassessment of Diagnostic Criteria in Patients With Portal Hypertension.

The American journal of gastroenterology·2022
Same author

Low-Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events.

Journal of the American Heart Association·2020
Same author

A comparison of three apolipoprotein B methods and their associations with incident coronary heart disease risk over a 12-year follow-up period: The Multi-Ethnic Study of Atherosclerosis.

Journal of clinical lipidology·2018
Same author

Lipoprotein(a) Mass Levels Increase Significantly According to <i>APOE</i> Genotype: An Analysis of 431 239 Patients.

Arteriosclerosis, thrombosis, and vascular biology·2017
Same journal

Advances in Hemostasis Laboratory Testing.

Clinics in laboratory medicine·2026
Same journal

Extracellular Vesicles in Hemostasis.

Clinics in laboratory medicine·2026
Same journal

Thrombin Generation Assay: Ready for Prime Time.

Clinics in laboratory medicine·2026
Same journal

Viscoelastic Testing for the Laboratorian: Recent Advances and Practical Advice.

Clinics in laboratory medicine·2026
Same journal

Practical Recommendations for Harmonization of Hemostasis Testing Across Hospital Sites.

Clinics in laboratory medicine·2026
Same journal

The Role of Hypoxia in Vascular Endothelial Dysfunction and Venous Thromboembolism.

Clinics in laboratory medicine·2026
See all related articles

Lipoprotein-associated phospholipase A2 (LP-PLA2) is an inflammatory marker linked to cardiovascular disease (CVD) risk. Research explores LP-PLA2

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Inflammation Research

Background:

  • Lipoprotein-associated phospholipase A2 (LP-PLA2) is an emerging inflammatory marker associated with cardiovascular disease (CVD) risk.
  • Epidemiologic studies show a correlation between plasma LP-PLA2 levels and cardiovascular event risk.
  • Current treatments like statins and fenofibrates can lower LP-PLA2 concentrations.

Purpose of the Study:

  • To review recent studies on LP-PLA2 in the context of CVD.
  • To discuss the proposed mechanisms of action for LP-PLA2.
  • To describe methods for measuring LP-PLA2 and their clinical applications.

Main Methods:

  • Review of recent scientific literature and clinical trial data.
  • Analysis of proposed biochemical pathways involving LP-PLA2.

Related Experiment Videos

  • Evaluation of diagnostic and clinical utility of LP-PLA2 measurement techniques.

    • Main Results:

    • LP-PLA2 concentration is independently associated with cardiovascular event risk.
    • Statins and fenofibrates demonstrate efficacy in reducing plasma LP-PLA2 levels.
    • Specific LP-PLA2 inhibitors are under clinical investigation as a therapeutic strategy.

    Conclusions:

    • LP-PLA2 is a significant marker for assessing CVD risk.
    • LP-PLA2 presents a potential therapeutic target for cardiovascular conditions.
    • Further research is ongoing to validate LP-PLA2 inhibitors in clinical practice.